Skip to main content
Erschienen in: International Ophthalmology 6/2017

09.11.2016 | Original Paper

Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy

verfasst von: Makiko Katagiri, Jun Shoji, Satoshi Kato, Shigehiko Kitano, Yasuko Uchigata

Erschienen in: International Ophthalmology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the relationship between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and vascular endothelial growth factor (VEGF) and renal function, and correlations between vitreous sRAGE levels and proliferative diabetic retinopathy (PDR) activity.

Methods

We examined 33 eyes from 33 patients with diabetes mellitus who underwent a vitrectomy (eight patients in the non-PDR [NPDR] group and 25 in the PDR group). Serum creatinine levels and estimated glomerular filtration rate (eGFR) were measured and classified according to the chronic kidney disease (CKD)-staging method. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify vitreous sRAGE and VEGF levels.

Results

Vitreous sRAGE levels were significantly higher in PDR group compared to NPDR group (p = 0.00003). Vitreous sRAGE levels were significantly higher in patients with CKD stage 5 (end-stage renal failure or hemodialysis) than in patients with CKD stage 1 or 2 (p < 0.01) and 3 or 4 (p < 0.05), and were significantly correlated with eGFR (r = − 0.490, p = 0.007) and creatinine levels (r = 0.484, p = 0.006). Within the PDR group, patients with low (<27 pg/mL) sRAGE levels required repeat vitreous surgeries for early postoperative vitreous hemorrhage significantly more frequently than those with high (≥27 pg/mL) sRAGE levels (p = 0.0067).

Conclusions

Vitreous sRAGE levels were significantly correlated with renal function, and low vitreous sRAGE levels in patients with PDR were associated with postoperative vitreous hemorrhage. Vitreous sRAGE may be a useful biomarker for renal dysfunction associated with diabetic retinopathy.
Literatur
2.
Zurück zum Zitat Lee WJ, Sobrin L, Kang MH, Seong M, Kim YJ, Yi JH, Miller JW, Cho HY (2014) Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye 28:1119–1125CrossRefPubMedPubMedCentral Lee WJ, Sobrin L, Kang MH, Seong M, Kim YJ, Yi JH, Miller JW, Cho HY (2014) Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression. Eye 28:1119–1125CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Matsuo T (2006) Disappearance of diabetic macular hard exudates after hemodialysis introduction. Acta Med Okayama 60:201–205PubMed Matsuo T (2006) Disappearance of diabetic macular hard exudates after hemodialysis introduction. Acta Med Okayama 60:201–205PubMed
4.
Zurück zum Zitat Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101CrossRefPubMed Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101CrossRefPubMed
5.
Zurück zum Zitat Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299CrossRefPubMed Yamagishi S, Imaizumi T (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279–2299CrossRefPubMed
6.
Zurück zum Zitat Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi M, Yamamoto H (2007) Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 77:S30–S40CrossRefPubMed Yamamoto Y, Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi M, Yamamoto H (2007) Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells. Diabetes Res Clin Pract 77:S30–S40CrossRefPubMed
7.
Zurück zum Zitat Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGE) theory in diabetic complication. Curr Mol Med 6:351–358CrossRefPubMed Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGE) theory in diabetic complication. Curr Mol Med 6:351–358CrossRefPubMed
8.
Zurück zum Zitat Ai J, Liu Y, Sun JH (2013) Advanced glycation end-products stimulate basic fibroblast growth factor expression in cultured Müller cells. Mol Med Rep 7:16–20CrossRefPubMed Ai J, Liu Y, Sun JH (2013) Advanced glycation end-products stimulate basic fibroblast growth factor expression in cultured Müller cells. Mol Med Rep 7:16–20CrossRefPubMed
9.
Zurück zum Zitat Zong H, Ward A, Madden A, Yong PH, Limb GA, Curis TM, Stitt AW (2010) Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products(RAGE). Diabetologia 53:2656–2666CrossRefPubMed Zong H, Ward A, Madden A, Yong PH, Limb GA, Curis TM, Stitt AW (2010) Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products(RAGE). Diabetologia 53:2656–2666CrossRefPubMed
10.
Zurück zum Zitat Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48:858–865CrossRefPubMed Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48:858–865CrossRefPubMed
11.
Zurück zum Zitat Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406–411CrossRefPubMed Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T (2006) Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47:406–411CrossRefPubMed
12.
Zurück zum Zitat Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026CrossRefPubMed Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T (2007) Receptor for advanced glycation end products—soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22:2020–2026CrossRefPubMed
13.
Zurück zum Zitat Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B (2015) Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 30:84–91CrossRefPubMed Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B (2015) Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease stage 5 patients. Nephrol Dial Transplant 30:84–91CrossRefPubMed
14.
Zurück zum Zitat Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis. Diabetes Care 32:1218–1220CrossRefPubMedPubMedCentral Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis. Diabetes Care 32:1218–1220CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler ThrombVasc Biol 25:1032–1037CrossRef Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler ThrombVasc Biol 25:1032–1037CrossRef
16.
Zurück zum Zitat Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC (2013) sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62:2116–2121CrossRefPubMedPubMedCentral Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC (2013) sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62:2116–2121CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed
18.
Zurück zum Zitat Kidney disease: Improving global outcomes (KDIGO) CKD work group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef Kidney disease: Improving global outcomes (KDIGO) CKD work group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150CrossRef
19.
Zurück zum Zitat Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-CE, Tsang TC, Stern D (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987–14997PubMed Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan Y-CE, Tsang TC, Stern D (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987–14997PubMed
20.
Zurück zum Zitat Takagi H, King GL, Aiello LP (1996) Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016–1023CrossRefPubMed Takagi H, King GL, Aiello LP (1996) Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016–1023CrossRefPubMed
21.
Zurück zum Zitat Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807–815CrossRefPubMed Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 82:807–815CrossRefPubMed
22.
Zurück zum Zitat El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, Al-Shabrawey M (2011) High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis 17:1829–1838PubMedPubMedCentral El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, Al-Shabrawey M (2011) High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis 17:1829–1838PubMedPubMedCentral
23.
Zurück zum Zitat Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916–2924CrossRefPubMed Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916–2924CrossRefPubMed
Metadaten
Titel
Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy
verfasst von
Makiko Katagiri
Jun Shoji
Satoshi Kato
Shigehiko Kitano
Yasuko Uchigata
Publikationsdatum
09.11.2016
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2017
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-016-0389-y

Weitere Artikel der Ausgabe 6/2017

International Ophthalmology 6/2017 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.